GM-CSF augments the IL-4-induced cytotoxic activity of human mononuclear cells in the presence of the mouse monoclonal antibody 17-1A

E. Reali, H. Mellstedt, G. Masucci

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background - The therapeutic effect of various modulators of the immune system might be increased if they are combined. Information on their activity using different schedules may be obtained from in vitro analyses. Methods - In this study, human peripheral blood mononuclear cells (lymphocytes and monocytes)(PBMC) were treated at the same time or sequentially with GM-CSF and IL-4 for different periods. Cytokine-activated PBMC were tested for cytolytic activity in a 18-h antibody-dependent cellular cytotoxicity (ADCC) assay using MAb 17-1A (mouse IgG2a) against SW1116 (a human colorectal carcinoma cell line). Results - The simultaneous incubation of effector cells with both cytokines did not increase the cytotoxicity induced by IL-4 or GM- CSF separately. Priming of PBMC with GM-CSF at the optimal concentration (10-3 μg/ml) for 1, 2 and 4h significantly enhanced the subsequent IL-4 induced activation of PBMC used at the optimal concentration (10-3 μg/ml). GM-CSF also augmented the cytotoxicity at a suboptimal concentration (10-4 μg/ml), but the lytic capability was less pronounced. Initial exposure of PBMC to IL-4 at optimal or suboptimal concentrations followed by stimulation with GM-CSF had no synergistic effect on ADCC. Conclusions - These results might have relevance as preliminary information to exploit the concept of combining different biological therapeutic agents for clinical protocols in cancer patients.

Original languageEnglish
Pages (from-to)116-122
Number of pages7
JournalCancer Journal (United States)
Volume6
Issue number3
Publication statusPublished - 1993

Fingerprint

Granulocyte-Macrophage Colony-Stimulating Factor
Human Activities
Interleukin-4
Cytokines
Antibodies
Biological Factors
Therapeutic Uses
Clinical Protocols
Monocytes
Colorectal Neoplasms
Immune System
Blood Cells
Appointments and Schedules
Edrecolomab
Lymphocytes
Cell Line
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

GM-CSF augments the IL-4-induced cytotoxic activity of human mononuclear cells in the presence of the mouse monoclonal antibody 17-1A. / Reali, E.; Mellstedt, H.; Masucci, G.

In: Cancer Journal (United States), Vol. 6, No. 3, 1993, p. 116-122.

Research output: Contribution to journalArticle

@article{d7265f8f380142b79300035040ca0c3b,
title = "GM-CSF augments the IL-4-induced cytotoxic activity of human mononuclear cells in the presence of the mouse monoclonal antibody 17-1A",
abstract = "Background - The therapeutic effect of various modulators of the immune system might be increased if they are combined. Information on their activity using different schedules may be obtained from in vitro analyses. Methods - In this study, human peripheral blood mononuclear cells (lymphocytes and monocytes)(PBMC) were treated at the same time or sequentially with GM-CSF and IL-4 for different periods. Cytokine-activated PBMC were tested for cytolytic activity in a 18-h antibody-dependent cellular cytotoxicity (ADCC) assay using MAb 17-1A (mouse IgG2a) against SW1116 (a human colorectal carcinoma cell line). Results - The simultaneous incubation of effector cells with both cytokines did not increase the cytotoxicity induced by IL-4 or GM- CSF separately. Priming of PBMC with GM-CSF at the optimal concentration (10-3 μg/ml) for 1, 2 and 4h significantly enhanced the subsequent IL-4 induced activation of PBMC used at the optimal concentration (10-3 μg/ml). GM-CSF also augmented the cytotoxicity at a suboptimal concentration (10-4 μg/ml), but the lytic capability was less pronounced. Initial exposure of PBMC to IL-4 at optimal or suboptimal concentrations followed by stimulation with GM-CSF had no synergistic effect on ADCC. Conclusions - These results might have relevance as preliminary information to exploit the concept of combining different biological therapeutic agents for clinical protocols in cancer patients.",
author = "E. Reali and H. Mellstedt and G. Masucci",
year = "1993",
language = "English",
volume = "6",
pages = "116--122",
journal = "Cancer Journal from Scientific American",
issn = "1528-9117",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "3",

}

TY - JOUR

T1 - GM-CSF augments the IL-4-induced cytotoxic activity of human mononuclear cells in the presence of the mouse monoclonal antibody 17-1A

AU - Reali, E.

AU - Mellstedt, H.

AU - Masucci, G.

PY - 1993

Y1 - 1993

N2 - Background - The therapeutic effect of various modulators of the immune system might be increased if they are combined. Information on their activity using different schedules may be obtained from in vitro analyses. Methods - In this study, human peripheral blood mononuclear cells (lymphocytes and monocytes)(PBMC) were treated at the same time or sequentially with GM-CSF and IL-4 for different periods. Cytokine-activated PBMC were tested for cytolytic activity in a 18-h antibody-dependent cellular cytotoxicity (ADCC) assay using MAb 17-1A (mouse IgG2a) against SW1116 (a human colorectal carcinoma cell line). Results - The simultaneous incubation of effector cells with both cytokines did not increase the cytotoxicity induced by IL-4 or GM- CSF separately. Priming of PBMC with GM-CSF at the optimal concentration (10-3 μg/ml) for 1, 2 and 4h significantly enhanced the subsequent IL-4 induced activation of PBMC used at the optimal concentration (10-3 μg/ml). GM-CSF also augmented the cytotoxicity at a suboptimal concentration (10-4 μg/ml), but the lytic capability was less pronounced. Initial exposure of PBMC to IL-4 at optimal or suboptimal concentrations followed by stimulation with GM-CSF had no synergistic effect on ADCC. Conclusions - These results might have relevance as preliminary information to exploit the concept of combining different biological therapeutic agents for clinical protocols in cancer patients.

AB - Background - The therapeutic effect of various modulators of the immune system might be increased if they are combined. Information on their activity using different schedules may be obtained from in vitro analyses. Methods - In this study, human peripheral blood mononuclear cells (lymphocytes and monocytes)(PBMC) were treated at the same time or sequentially with GM-CSF and IL-4 for different periods. Cytokine-activated PBMC were tested for cytolytic activity in a 18-h antibody-dependent cellular cytotoxicity (ADCC) assay using MAb 17-1A (mouse IgG2a) against SW1116 (a human colorectal carcinoma cell line). Results - The simultaneous incubation of effector cells with both cytokines did not increase the cytotoxicity induced by IL-4 or GM- CSF separately. Priming of PBMC with GM-CSF at the optimal concentration (10-3 μg/ml) for 1, 2 and 4h significantly enhanced the subsequent IL-4 induced activation of PBMC used at the optimal concentration (10-3 μg/ml). GM-CSF also augmented the cytotoxicity at a suboptimal concentration (10-4 μg/ml), but the lytic capability was less pronounced. Initial exposure of PBMC to IL-4 at optimal or suboptimal concentrations followed by stimulation with GM-CSF had no synergistic effect on ADCC. Conclusions - These results might have relevance as preliminary information to exploit the concept of combining different biological therapeutic agents for clinical protocols in cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0027301411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027301411&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027301411

VL - 6

SP - 116

EP - 122

JO - Cancer Journal from Scientific American

JF - Cancer Journal from Scientific American

SN - 1528-9117

IS - 3

ER -